Physician

Angela Jain, M.D.

According to 2025 Medicare claims, Angela Jain, M.D. (NPI: 1760624290) practices hematopoietic cell transplantation and cellular therapy in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Philadelphia, PA. This provider's primary affiliated billing organization is TEMPLE FACULTY PRACTICE PLAN, INC (NPI: 1417430166; TIN: 831002191) and primary practice location at 19111-2434.

Jain's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 195 traditional Medicare patients, billed 581 HCPCS/CPT codes, and received $48,628 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 996 prescription claims across 205 beneficiaries totaling $3,199,395 in drug costs, led by Ibrance (Palbociclib). 2022 DME data shows 11 claims. Open Payments data shows 8 records totaling $547. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $20,766 to $48,628. Similarly, Part D prescription costs have moved sharply higher in recent years, from $38,766 to $3,199,395. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	81	274	$20,766
2016	94	337	$22,935
2017	137	348	$25,176
2018	181	461	$32,929
2019	198	600	$38,898
2020	203	648	$40,048
2021	203	550	$44,484
2022	231	575	$50,083
2023	253	589	$50,611
2024	195	581	$48,628

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	45	275	$38,766
2016	53	296	$29,380
2017	98	448	$343,194
2018	129	607	$352,786
2019	163	914	$1,144,291
2020	165	889	$1,111,418
2021	162	737	$841,167
2022	149	802	$817,980
2023	169	863	$1,324,005
2024	205	996	$3,199,395

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	24	$1,941
2018	N/R	34	$2,878
2019	N/R	N/R	N/R
2020	N/R	11	$209
2021	N/R	91	$43,378
2022	N/R	11	$208
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	13	13	$147
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	51	127	$114
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	26	26	$105
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	141	313	$75
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	66	75	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	72	2,016	$1,099,583
Lenvima	Lenvatinib Mesylate	37	1,110	$866,294
Verzenio	Abemaciclib	53	1,484	$809,540
Lynparza	Olaparib	13	390	$212,116
Mekinist	Trametinib Dimethyl Sulfoxide	14	420	$86,895

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$232	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$315	Genmab U.S., Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Angela Jain, M.D.?

Tedicare shows public-source Medicare data for Angela Jain, M.D. (NPI 1760624290), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Angela Jain, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Angela Jain, M.D.?

Angela Jain, M.D. is linked to TEMPLE FACULTY PRACTICE PLAN, INC (billing NPI 1417430166) in the available physician profile data.

Does Angela Jain, M.D. have Open Payments data?

Angela Jain, M.D. has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.